Written and maintained by CASRAI Editorial Board
Published
On this page
The SOAP note Plan section is the actionable, forward-looking conclusion of a clinical progress note where the treating clinician translates diagnostic synthesis into concrete medical orders, pharmacotherapy adjustments, patient education, and follow-up safety parameters. First formalized by Dr. Lawrence L. Weed in 1968 as part of the Problem-Oriented Medical Record (POMR), the Plan (`P`) pairs directly with the SOAP note Assessment (`A`)—either as two consecutive headings or merged into a unified, numbered problem-based Assessment and Plan (A/P)—serving as the primary legal and billing justification for clinical decision-making in the Electronic Health Record (EHR).
What Belongs in the Plan Section of a Clinical SOAP Note?
In Lawrence Weed’s classical POMR formulation and modern hospital clinical documentation standards, every active clinical problem addressed in the Plan section is organized around four functional pillars (`Dx`, `Tx`, `Pt Ed`, and `Disposition / Follow-Up`):
- Diagnostic Plan (
Dx— Further Workup & Monitoring): Laboratory panels, microbiology cultures, diagnostic imaging studies, electrocardiograms, pathology biopsies, or physiological monitoring ordered to confirm a working diagnosis, rule out high-acuity differential diagnoses, or monitor organ toxicity—along with the clinical rationale for ordering (or deliberately deferring) each study. - Therapeutic Plan (
Tx— Pharmacologic, Procedural & Non-Pharmacologic Interventions):- Medication Management: New prescriptions, dose titrations, discontinuations, or explicit continuation of chronic regimens (specifying drug name, dose, route, frequency, and duration).
- Procedures & Consultations: Bedside or operative procedures performed or scheduled, plus specialty referrals (physical therapy, cardiology, behavioral health).
- Patient Education and Shared Decision-Making (
Pt Ed): Documentation of risk-benefit discussions, medication side-effect counseling, lifestyle/dietary modifications, and the patient’s understanding and agreement with the treatment plan. - Disposition, Follow-Up Interval, and Return Precautions (Safety-Netting): Target timeframe for the next clinic visit or inpatient reassessment, pending test follow-up ownership, and explicit red-flag return precautions (specific symptoms that should prompt the patient to seek immediate Emergency Department evaluation).
How Do You Structure a Problem-Based Assessment and Plan (A/P) for Complex Inpatient and Outpatient Encounters?
For patients presenting with multiple comorbidities, separating all assessments into one paragraph and all plans into a separate bulleted list forces readers to cross-reference which order belongs to which diagnosis. Modern inpatient and ambulatory practices (as well as AI SOAP note generators) use a combined problem-based Assessment and Plan (or the inverted APSO note format) where each numbered clinical problem contains its own concise synthesis statement followed immediately by its hyphenated action items:
Worked Example 1: Outpatient Primary Care Problem-Based SOAP Plan
ASSESSMENT & PLAN:
1. Type 2 Diabetes Mellitus without complications, uncontrolled (ICD-10-CM E11.65):
62-year-old male with HbA1c rising from 7.4% to 8.6% over 6 months despite maximal tolerated metformin (1,000 mg PO BID); eGFR stable at 68 mL/min/1.73m², urine albumin-to-creatinine ratio (uACR) 42 mg/g.
– Tx: Initiate empagliflozin (Jardiance) 10 mg PO once daily for glycemic control and cardiorenal protection; continue metformin ER 1,000 mg PO BID.
– Dx: Repeat point-of-care HbA1c and Basic Metabolic Panel (BMP) in 3 months.
– Pt Ed: Counseled on SGLT2 inhibitor mechanism, importance of daily hydration, perineal hygiene to reduce mycotic genital infection risk, and rare risk of euglycemic diabetic ketoacidosis (hold medication 3 days prior to any elective surgery or during acute febrile GI illness).2. Essential Hypertension, at goal (ICD-10-CM I10):
Home BP log averaging 124/76 mmHg; clinic repeat BP 126/78 mmHg today.
– Tx: Continue lisinopril 20 mg PO daily.
– Dx: Monitor serum potassium and creatinine on 3-month BMP.3. Disposition & Follow-Up:
– Return to clinic in 12 weeks with fasting morning labs 1 week prior. Patient instructed to call clinic or seek urgent care for dizziness, orthostasis, dysuria, or persistent nausea/vomiting.
Worked Example 2: Inpatient Internal Medicine Problem-Based A/P
#1. Acute Decompensated Heart Failure (HFrEF, LVEF 30%, ICD-10-CM I50.23):
Likely precipitated by dietary sodium indiscretion; net negative 1.8 L over past 24 hours on IV loop diuresis with improved bibasilar rales and oxygen saturation 96% on room air.
– Tx: Continue bumetanide 2 mg IV BID today; transition to oral torsemide 20 mg PO daily tomorrow if net negative > 1.5 L achieved. Continue guideline-directed medical therapy (sacubitril/valsartan 49/51 mg BID, carvedilol 12.5 mg BID, spironolactone 25 mg daily).
– Dx: Strict I&Os, daily standing weights, daily morning BMP and magnesium (replete K+ > 4.0 mEq/L, Mg2+ > 2.0 mg/dL).
– Prophylaxis / Disposition: Subcutaneous enoxaparin 40 mg daily for VTE prophylaxis; heart failure nursing education consult placed.
How Does the Plan Section Support AMA E/M Medical Decision Making (MDM) Risk and LOINC 18776-5 Mapping?
In both revenue cycle auditing and healthcare interoperability, the Plan section carries specific regulatory and technical mappings:
| Governance Domain | Standard / Code | Required Documentation Elements in the SOAP Plan |
|---|---|---|
| AMA CPT E/M MDM Level 4 (Moderate Risk — e.g., 99204 / 99214) | AMA 2021/2023 E/M Guidelines | Documenting prescription drug management (starting, titrating, discontinuing, or clinically justifying continuation of a prescription medication), decision regarding minor surgery with identified patient risk factors, or diagnosis/treatment significantly limited by Social Determinants of Health (SDOH). |
| AMA CPT E/M MDM Level 5 (High Risk — e.g., 99205 / 99215) | AMA 2021/2023 E/M Guidelines | Documenting drug therapy requiring intensive monitoring for toxicity (e.g., cytotoxic chemotherapy, warfarin, lithium, or immunosuppressants with scheduled lab toxicity intervals), decision regarding elective major surgery with risk factors, emergency major surgery, hospitalization, or DNR/de-escalation of care. |
| HL7 C-CDA & FHIR Clinical Note Section Tagging | LOINC 18776-5 (Plan of care note) & LOINC 51847-2 (Assessment and plan note) |
In HL7 C-CDA R2.1 (`2.16.840.1.113883.10.20.22.2.10`) and HL7 FHIR R4 `Composition.section`, a standalone Plan section is coded as LOINC 18776-5 (while a combined A/P section is coded as 51847-2), linking to discrete FHIR CarePlan, MedicationRequest, and ServiceRequest resources. |
Frequently Asked Questions
What belongs in the Plan section of a clinical SOAP note?
The Plan section of a SOAP note contains four clinical elements for each active problem: (1) the Diagnostic Plan (labs, imaging, or monitoring ordered and their rationale), (2) the Therapeutic Plan (medications started, adjusted, or continued, plus procedures and specialty referrals), (3) Patient Education (shared decision-making, risk/side-effect counseling, and lifestyle guidance), and (4) Disposition and Follow-Up (next appointment timeframe and red-flag return precautions).
How do you structure a problem-based Assessment and Plan (A/P) for complex inpatient and outpatient encounters?
In a problem-based Assessment and Plan (A/P), active conditions are listed in priority order as numbered headings (`#1`, `#2`, `#3`) paired with their specific ICD-10-CM codes. Directly beneath each problem heading, the clinician writes a 1- to 2-sentence clinical synthesis (disease stability, severity, and etiology) followed immediately by bulleted diagnostic (`Dx`), therapeutic (`Tx`), and counseling (`Pt Ed`) plan actions specific to that problem.
How does the Plan section support AMA E/M Medical Decision Making (MDM) risk and LOINC 18776-5 mapping?
Under AMA 2021/2023 CPT E/M guidelines, the Plan section documents the third element of Medical Decision Making (Risk of Complications and/or Morbidity or Mortality of Patient Management), such as prescription drug management (Moderate Risk, Level 4) or intensive drug toxicity monitoring and hospitalization decisions (High Risk, Level 5). In HL7 C-CDA and FHIR document exchange, the Plan section is standardized under LOINC code 18776-5 (Plan of care note), or 51847-2 when combined as an Assessment and Plan section.







